Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…

Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya

Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year. It also…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna signs with Kenya for first mRNA facility in Africa

Moderna says it has signed a memorandum of understanding with Kenya’s government for the drugmaker's first mRNA vaccine manufacturing facility in Africa

The Independent UK

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 43 strange trades.

Benzinga

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Benzinga

EU clears Moderna shot for young kids, Pfizer boosters

The European Medicines Agency said it has authorized Moderna’s coronavirus vaccine for children aged six to 11, in addition to recommending booster shots of Pfizer’s vaccine for those aged 12 and over

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

COVID vax: Pregnant women left behind

Clinical trials of COVID vaccines excluded pregnant people, which left many wondering whether to get vaccinated

Salon

A South African company addresses vaccine supply inequity, despite Canada's lack of support

Since late 2020, the inequitable access across the globe to COVID-19 vaccines has been a glaring problem. But a remarkable achievement earlier this month offers hope that the supply of vaccines to developing countries will improve: Afrigen Biologics, a South African based company, produced its own version of Moderna’s mRNA…

The Conversation

Expert Ratings For Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

3 Worst Performing Stocks in the S&P 500 Year-to-Date

S&P 500 stocks have been plummeting amid concerns about tighter monetary policy and the escalating war between Russia and Ukraine. This has triggered further selloffs, causing renowned stocks PayPal (PYPL), Moderna (MRNA), and EPAM Systems (EPAM) to lose momentum lately. Let’s discuss.

StockNews.com

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Benzinga

Drugmakers Reap Billions Meeting Covid-19 Needs

Healthcare companies that came up with effective Covid-19 vaccines, treatments and tests are seeing a huge financial payoff and are starting to spend their cash, while grappling with questions about whether the growth is sustainable.

Bangkok Post

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

Kia Slade was seven months pregnant, unvaccinated, and fighting for breath, her oxygen levels plummeting, when her son came into the world last May.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Moderna, Inc.

Benzinga

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Investors Business Daily

Stock Market Pares Losses After Russian Invasion; Nasdaq Escapes Most Of The Carnage

The stock market tumbled Thursday on Russia's invasion of Ukraine, but the tech-heavy Nasdaq escaped most of the carnage.

Benzinga

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Investors Business Daily

Moderna Pops On Strong Covid Vaccine Sales, Though Offers Light Outlook

Moderna stock popped Thursday after sales of its Covid vaccine outperformed Wall Street's forecasts, though guidance for 2022 came in light.

Benzinga

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

The Independent UK

COVID-19 vaccine sales push Moderna to $12B profit in 2021

Moderna’s COVID-19 vaccine brought in nearly $7 billion in the final quarter of 2021, and the drugmaker says it has signed purchase agreements for another $19 billion in sales this year

Benzinga

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has en

1 … 33 34 35 36

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.